JP2012505225A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012505225A5 JP2012505225A5 JP2011531140A JP2011531140A JP2012505225A5 JP 2012505225 A5 JP2012505225 A5 JP 2012505225A5 JP 2011531140 A JP2011531140 A JP 2011531140A JP 2011531140 A JP2011531140 A JP 2011531140A JP 2012505225 A5 JP2012505225 A5 JP 2012505225A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound
- atropisomer
- phenyl
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 55
- 239000000203 mixture Substances 0.000 claims description 26
- 241001465754 Metazoa Species 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 12
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 10
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 9
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 9
- 229940124597 therapeutic agent Drugs 0.000 claims description 9
- 150000001204 N-oxides Chemical class 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 8
- 125000005843 halogen group Chemical group 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 230000000069 prophylactic effect Effects 0.000 claims description 7
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 claims description 6
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 claims description 6
- 229940083712 aldosterone antagonist Drugs 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 206010020772 Hypertension Diseases 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 4
- 206010019280 Heart failures Diseases 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 206010002383 Angina Pectoris Diseases 0.000 claims description 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 208000016998 Conn syndrome Diseases 0.000 claims description 3
- 206010016654 Fibrosis Diseases 0.000 claims description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 3
- 206010008118 cerebral infarction Diseases 0.000 claims description 3
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 230000004761 fibrosis Effects 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 208000017169 kidney disease Diseases 0.000 claims description 3
- 208000013846 primary aldosteronism Diseases 0.000 claims description 3
- AAJDXRXNKJLUSF-UHFFFAOYSA-N 1-(3-hydroxybutan-2-yl)-4-methyl-n-(4-methylsulfonylphenyl)-5-[2-(trifluoromethyl)phenyl]pyrrole-3-carboxamide Chemical compound CC1=C(C=2C(=CC=CC=2)C(F)(F)F)N(C(C)C(O)C)C=C1C(=O)NC1=CC=C(S(C)(=O)=O)C=C1 AAJDXRXNKJLUSF-UHFFFAOYSA-N 0.000 claims description 2
- AAJDXRXNKJLUSF-CVEARBPZSA-N 1-[(2r,3s)-3-hydroxybutan-2-yl]-4-methyl-n-(4-methylsulfonylphenyl)-5-[2-(trifluoromethyl)phenyl]pyrrole-3-carboxamide Chemical compound CC1=C(C=2C(=CC=CC=2)C(F)(F)F)N([C@H](C)[C@@H](O)C)C=C1C(=O)NC1=CC=C(S(C)(=O)=O)C=C1 AAJDXRXNKJLUSF-CVEARBPZSA-N 0.000 claims description 2
- -1 2-hydroxy-1-methylpropyl group Chemical group 0.000 claims description 2
- WSRMVIRQHUZSGA-UHFFFAOYSA-N 5-(2-chloro-4-fluorophenyl)-1-(3-hydroxybutan-2-yl)-4-methyl-n-(4-methylsulfonylphenyl)pyrrole-3-carboxamide Chemical compound CC1=C(C=2C(=CC(F)=CC=2)Cl)N(C(C)C(O)C)C=C1C(=O)NC1=CC=C(S(C)(=O)=O)C=C1 WSRMVIRQHUZSGA-UHFFFAOYSA-N 0.000 claims description 2
- WSRMVIRQHUZSGA-CABCVRRESA-N 5-(2-chloro-4-fluorophenyl)-1-[(2r,3s)-3-hydroxybutan-2-yl]-4-methyl-n-(4-methylsulfonylphenyl)pyrrole-3-carboxamide Chemical compound CC1=C(C=2C(=CC(F)=CC=2)Cl)N([C@H](C)[C@@H](O)C)C=C1C(=O)NC1=CC=C(S(C)(=O)=O)C=C1 WSRMVIRQHUZSGA-CABCVRRESA-N 0.000 claims description 2
- NHVGLTBLUNAPQE-UHFFFAOYSA-N 5-[4-chloro-2-(trifluoromethyl)phenyl]-1-(3-hydroxybutan-2-yl)-4-methyl-n-(4-methylsulfonylphenyl)pyrrole-3-carboxamide Chemical compound CC1=C(C=2C(=CC(Cl)=CC=2)C(F)(F)F)N(C(C)C(O)C)C=C1C(=O)NC1=CC=C(S(C)(=O)=O)C=C1 NHVGLTBLUNAPQE-UHFFFAOYSA-N 0.000 claims description 2
- NHVGLTBLUNAPQE-CABCVRRESA-N 5-[4-chloro-2-(trifluoromethyl)phenyl]-1-[(2r,3s)-3-hydroxybutan-2-yl]-4-methyl-n-(4-methylsulfonylphenyl)pyrrole-3-carboxamide Chemical compound CC1=C(C=2C(=CC(Cl)=CC=2)C(F)(F)F)N([C@H](C)[C@@H](O)C)C=C1C(=O)NC1=CC=C(S(C)(=O)=O)C=C1 NHVGLTBLUNAPQE-CABCVRRESA-N 0.000 claims description 2
- RKOXRANVRDCFQL-UHFFFAOYSA-N 5-[4-fluoro-2-(trifluoromethyl)phenyl]-1-(3-hydroxybutan-2-yl)-4-methyl-n-(4-methylsulfonylphenyl)pyrrole-3-carboxamide Chemical compound CC1=C(C=2C(=CC(F)=CC=2)C(F)(F)F)N(C(C)C(O)C)C=C1C(=O)NC1=CC=C(S(C)(=O)=O)C=C1 RKOXRANVRDCFQL-UHFFFAOYSA-N 0.000 claims description 2
- RKOXRANVRDCFQL-CABCVRRESA-N 5-[4-fluoro-2-(trifluoromethyl)phenyl]-1-[(2r,3s)-3-hydroxybutan-2-yl]-4-methyl-n-(4-methylsulfonylphenyl)pyrrole-3-carboxamide Chemical compound CC1=C(C=2C(=CC(F)=CC=2)C(F)(F)F)N([C@H](C)[C@@H](O)C)C=C1C(=O)NC1=CC=C(S(C)(=O)=O)C=C1 RKOXRANVRDCFQL-CABCVRRESA-N 0.000 claims description 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 2
- 206010030113 Oedema Diseases 0.000 claims description 2
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 11
- 0 *c1c(-c2c(*)cc(*)cc2)[n](*)cc1C(Nc(cc1)cc(*)c1S(*)(=O)=O)=O Chemical compound *c1c(-c2c(*)cc(*)cc2)[n](*)cc1C(Nc(cc1)cc(*)c1S(*)(=O)=O)=O 0.000 description 2
- 208000030090 Acute Disease Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 150000003233 pyrroles Chemical class 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10371508P | 2008-10-08 | 2008-10-08 | |
| US61/103,715 | 2008-10-08 | ||
| PCT/US2009/059847 WO2010042622A1 (en) | 2008-10-08 | 2009-10-07 | Atropisomers of (hydroxyalkyl) pyrrole derivatives |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014148858A Division JP6121952B2 (ja) | 2008-10-08 | 2014-07-22 | （ヒドロキシアルキル）ピロール誘導体のアトロプ異性体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012505225A JP2012505225A (ja) | 2012-03-01 |
| JP2012505225A5 true JP2012505225A5 (enExample) | 2012-11-22 |
| JP5767586B2 JP5767586B2 (ja) | 2015-08-19 |
Family
ID=41360127
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011531140A Active JP5767586B2 (ja) | 2008-10-08 | 2009-10-07 | （ヒドロキシアルキル）ピロール誘導体のアトロプ異性体 |
| JP2014148858A Active JP6121952B2 (ja) | 2008-10-08 | 2014-07-22 | （ヒドロキシアルキル）ピロール誘導体のアトロプ異性体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014148858A Active JP6121952B2 (ja) | 2008-10-08 | 2014-07-22 | （ヒドロキシアルキル）ピロール誘導体のアトロプ異性体 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8487117B2 (enExample) |
| EP (1) | EP2349997B1 (enExample) |
| JP (2) | JP5767586B2 (enExample) |
| KR (1) | KR101643285B1 (enExample) |
| CN (1) | CN102186817B (enExample) |
| AU (1) | AU2009302371B2 (enExample) |
| BR (1) | BRPI0920459B1 (enExample) |
| CA (1) | CA2736923C (enExample) |
| ES (1) | ES2547697T3 (enExample) |
| IL (1) | IL212170A (enExample) |
| TW (2) | TWI547479B (enExample) |
| WO (1) | WO2010042622A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE037007T2 (hu) | 2013-08-27 | 2018-08-28 | Daiichi Sankyo Co Ltd | Eljárás pirrol származék elõállítására és annak intermediere |
| WO2021078135A1 (zh) * | 2019-10-25 | 2021-04-29 | 广东东阳光药业有限公司 | 吡咯酰胺类化合物及其用途 |
| CA3213094A1 (en) * | 2021-03-30 | 2022-10-06 | Qiao ZONG | Crystalline form of pyrrole amide compound, preparation method therefor and use thereof |
| CN115784961A (zh) * | 2021-09-10 | 2023-03-14 | 上海鼎雅药物化学科技有限公司 | 埃沙西林酮及其中间体的合成方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006012642A2 (en) | 2004-07-30 | 2006-02-02 | Exelixis, Inc. | Pyrrole derivatives as pharmaceutical agents |
| BRPI0809656B8 (pt) * | 2007-04-09 | 2021-05-25 | Daiichi Sankyo Co Ltd | atropisômero, composto, agente profilático ou terapêutico, e, composição farmacêutica |
-
2009
- 2009-10-07 EP EP09737501.8A patent/EP2349997B1/en active Active
- 2009-10-07 US US13/122,147 patent/US8487117B2/en active Active
- 2009-10-07 AU AU2009302371A patent/AU2009302371B2/en active Active
- 2009-10-07 CA CA2736923A patent/CA2736923C/en active Active
- 2009-10-07 KR KR1020117010427A patent/KR101643285B1/ko active Active
- 2009-10-07 CN CN200980139822.5A patent/CN102186817B/zh active Active
- 2009-10-07 ES ES09737501.8T patent/ES2547697T3/es active Active
- 2009-10-07 JP JP2011531140A patent/JP5767586B2/ja active Active
- 2009-10-07 WO PCT/US2009/059847 patent/WO2010042622A1/en not_active Ceased
- 2009-10-07 BR BRPI0920459-8A patent/BRPI0920459B1/pt active IP Right Grant
- 2009-10-08 TW TW098134174A patent/TWI547479B/zh active
- 2009-10-08 TW TW104142529A patent/TWI593674B/zh active
-
2011
- 2011-04-06 IL IL212170A patent/IL212170A/en active IP Right Grant
-
2014
- 2014-07-22 JP JP2014148858A patent/JP6121952B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5966014B2 (ja) | 新規トリフルオロメチル−オキサジアゾール誘導体および疾患の処置におけるその使用 | |
| JP6464139B2 (ja) | ブロモドメイン含有タンパク質の阻害のための方法および組成物 | |
| RU2439068C2 (ru) | Модуляторы mglur5 | |
| RU2481330C2 (ru) | Азотсодержащее ароматическое гетероциклическое соединение | |
| JP2008513498A5 (enExample) | ||
| EP3194386A2 (en) | Sgc stimulators | |
| JP2011502958A5 (enExample) | ||
| JP2015531773A (ja) | スルファモイル−アリールアミド及びｂ型肝炎の治療のための薬剤としてのその使用 | |
| JP2022188052A (ja) | 痛風または高尿酸血症に関連する症状を処置または予防するための化合物、組成物、および方法 | |
| JP2008513499A5 (enExample) | ||
| JP2010515715A5 (enExample) | ||
| JP2008513515A5 (enExample) | ||
| JP2016506964A5 (ja) | ナトリウムチャネルの調節剤としてのキノリンおよびキノキサリンアミド | |
| JP2014518853A5 (enExample) | ||
| PE20081704A1 (es) | Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta-9 desaturasa | |
| JP2008513516A5 (enExample) | ||
| CA2674436A1 (en) | Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors | |
| UA104471C2 (uk) | ФАРМАЦЕВТИЧНА ДОЗОВАНА ФОРМА ДЛЯ ПЕРОРАЛЬНОГО ВВЕДЕННЯ ІНГІБІТОРУ СІМЕЙСТВА Bcl-2 | |
| JP2014526500A5 (enExample) | ||
| JP2010533160A5 (enExample) | ||
| EA200701361A1 (ru) | Конденсированные производные пиразола и способы лечения с их помощью заболеваний, вызванных нарушением обмена веществ | |
| KR20170055531A (ko) | 에스지씨 자극제 | |
| JP2010516701A5 (enExample) | ||
| JP2010516700A5 (enExample) | ||
| JP2012526769A5 (enExample) |